Literature DB >> 8751973

HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma.

C M Jackow1, J B McHam, A Friss, J Alvear, J R Reveille, M Duvic.   

Abstract

Cutaneous T-cell lymphoma (CTCL) may present with eczematous lesions, mycosis fungoides (MF), or as exfoliative erythroderma with circulating atypical cells, Sezary syndrome (SS). The "malignant" T cells are epidermotropic and clonal, but whether they respond to antigen stimulation is unknown. Because CD4+ lymphocytes recognize antigen presented by histocompatibility locus antigen (HLA) class II molecules, and HLA association have been found in autoimmune skin diseases, we determined by allele-specific oligonucleotide typing whether HLA-DR or DQ alleles were associated with CTCL and its two variants MF (n = 47) and SS (n = 23). Phenotypic frequencies were compared by chi-square and Fisher exact test, and p values were corrected independently for either 12 DR or 15 DQ alleles. HLA-DR5, previously associated with MF, was significantly increased in all 70 CTCL patients (31.5%) versus controls (11%) (uncorrected p value [Pnc] = 0.000038, odds ratio [OR] = 3.9, 1.9 < OR < 8.1), in MF patients (34%) (Pnc = 0.000047, OR = 3.62, 1.9 < OR < 10), and in SS patients (26%) (Pnc = 0.03, OR = 3, 0.9 < OR < 9.3). HLA-DQB1*03 alleles (0301, 0302, and 0303) were increased in 72% of all CTCL patients versus 49% of controls (corrected p value [Pc] = 0.014, OR = 2.7, 1.4 < OR < 5.1), in SS (82%) (Pc = 0.05, OR = 4.7, 1.4 < OR < 5), and in MF (67%) (Pnc = 0.024, OR = 2.15, 1 < OR < 4.5). DQB1*0502 was strongly increased in SS patients (Pc = 0.045, OR = 7.75, 1.25 < OR < 48). Although HLA-DQB1*0603 and HLA-DR6 (1301, 1302, and 1402) were decreased in all groups, the decreases were not statistically significant. These data suggest that certain HLA-DRB and DQB1 alleles, also associated with other T-cell-mediated skin diseases, may participate in the pathogenesis of or susceptibility to CTCL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8751973     DOI: 10.1111/1523-1747.ep12363352

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  20 in total

1.  Specific HLA-DQB1 alleles associated with risk for development of hepatocellular carcinoma: a meta-analysis.

Authors:  Yong-Ning Xin; Zhong-Hua Lin; Xiang-Jun Jiang; Shu-Hui Zhan; Quan-Jiang Dong; Qing Wang; Shi-Ying Xuan
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

2.  Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries.

Authors:  Ivan V Litvinov; Michael T Tetzlaff; Elham Rahme; Youssef Habel; David R Risser; Pamela Gangar; Michelle A Jennings; Kevin Pehr; Victor G Prieto; Denis Sasseville; Madeleine Duvic
Journal:  Cancer       Date:  2015-02-27       Impact factor: 6.860

Review 3.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

4.  Association between HLA-DQB1 gene and patients with acute lymphoblastic leukemia (ALL).

Authors:  Elias Orouji; Jalil Tavakkol Afshari; Zahra Badiee; Abbas Shirdel; Afrouz Alipour
Journal:  Int J Hematol       Date:  2012-03-21       Impact factor: 2.490

Review 5.  T-cell Lymphoma Epidemiology: the Known and Unknown.

Authors:  Anh Phan; Rachel Veldman; Mary Jo Lechowicz
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 6.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 7.  Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047

8.  Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.

Authors:  Madeleine Duvic; Jenny Vu
Journal:  Biologics       Date:  2007-12

Review 9.  Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma.

Authors:  Andreas Willerslev-Olsen; Thorbjørn Krejsgaard; Lise M Lindahl; Charlotte Menne Bonefeld; Mariusz A Wasik; Sergei B Koralov; Carsten Geisler; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Toxins (Basel)       Date:  2013-08-14       Impact factor: 4.546

10.  Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.

Authors:  Alexandra C Hristov; Trilokraj Tejasvi; Ryan A Wilcox
Journal:  Am J Hematol       Date:  2021-08-02       Impact factor: 13.265

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.